AbbVie (NYSE:ABBV) continued gains for seven straight sessions, as the stock closed 1.3% higher at $189.90 on Friday. The North Chicago-based pharma giant gained about 1% in the preceding six ...

Humira’s global sales fell nearly 50%, thanks to biosimilar competition, and aesthetics—especially Botox—saw a double-digit dip due to wobbly consumer sentiment. Still, AbbVie raised its full-year EPS ...

With this approval, Yuflyma is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths. Yuflyma is a high-concentration ...

AbbVie reported solid Q1 2025 results, raising full-year guidance and showing strong growth in Skyrizi and Rinvoq offsetting Humira's decline. Despite entering the obesity market, AbbVie's ...

AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the loss of exclusivity (“LOE”) and biosimilar erosion.

Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung ...

AbbVie is working hard to pivot beyond its blockbuster Humira, which faces stiff biosimilar competition, and investors are watching closely. Skyrizi and Rinvoq, two rising immunology stars, are ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms ...

AbbVie’s fourth quarter earnings exceeded expectations on both revenue and EPS, driven by continued growth in its immunology and neuroscience franchises, alongside stabilizing trends in Humira ...